Fig. 7 | Scientific Reports

Fig. 7

From: Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: a randomized, double-blind, and placebo-controlled trial

Fig. 7

Multivariate (A–E) and univariate (F–I) analyses of fecal metabolome over time of intervention in the placebo and RH 3201 groups. (A–C) Unsupervised principal component analysis (PCA) with an auto-scaling method. (D) Supervised partial least squares discriminant analysis (PLS-DA) with an auto-scaling method. (E) Discriminant metabolic features identified according to the Variable Importance in Projection (VIP) scores. The 15 most important metabolites with value of VIP score > 1.5 are reported. (F–I) Volcano plot analyses of differentially abundant fecal metabolites over time of intervention in the placebo and RH 3201 groups. RH 3201 versus placebo at 4-week (F) and 8-week (G). Changes on metabolite abundances of RH 3201 at 4-week (H) and 8-week (I) compared to the 0-week control. Blue and red dots represent significant decreases and increases in metabolites, respectively (p < 0.05). Gray dots represent all other metabolites identified in the dataset of which relative concentrations did not change significantly between the two groups.

Back to article page